GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:00028322 | Cervix | CC | negative regulation of response to biotic stimulus | 27/2311 | 108/18723 | 2.27e-04 | 2.55e-03 | 27 |
GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
GO:00321022 | Cervix | CC | negative regulation of response to external stimulus | 75/2311 | 420/18723 | 5.96e-04 | 5.61e-03 | 75 |
GO:00450882 | Cervix | CC | regulation of innate immune response | 44/2311 | 218/18723 | 6.40e-04 | 5.97e-03 | 44 |
GO:00026983 | Cervix | CC | negative regulation of immune effector process | 26/2311 | 110/18723 | 7.40e-04 | 6.63e-03 | 26 |
GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
GO:00458243 | Cervix | CC | negative regulation of innate immune response | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
GO:0031348 | Cervix | CC | negative regulation of defense response | 48/2311 | 258/18723 | 2.30e-03 | 1.65e-02 | 48 |
GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
GO:0002822 | Cervix | CC | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/2311 | 168/18723 | 8.00e-03 | 4.18e-02 | 32 |
GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
GO:00304492 | Cervix | CC | regulation of complement activation | 7/2311 | 21/18723 | 1.04e-02 | 4.97e-02 | 7 |
GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
GO:000283212 | Esophagus | ESCC | negative regulation of response to biotic stimulus | 72/8552 | 108/18723 | 8.36e-06 | 8.11e-05 | 72 |
GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SUSD4 | SNV | Missense_Mutation | | c.1294N>T | p.Ser432Cys | p.S432C | Q5VX71 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SUSD4 | SNV | Missense_Mutation | rs756692002 | c.499G>A | p.Asp167Asn | p.D167N | Q5VX71 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SUSD4 | SNV | Missense_Mutation | | c.1045G>A | p.Ala349Thr | p.A349T | Q5VX71 | protein_coding | tolerated(0.7) | benign(0) | TCGA-BH-A0BQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SUSD4 | SNV | Missense_Mutation | rs774042536 | c.895N>G | p.Gln299Glu | p.Q299E | Q5VX71 | protein_coding | tolerated(0.28) | possibly_damaging(0.702) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
SUSD4 | SNV | Missense_Mutation | | c.545G>C | p.Arg182Thr | p.R182T | Q5VX71 | protein_coding | deleterious(0.01) | possibly_damaging(0.671) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SUSD4 | SNV | Missense_Mutation | rs750308474 | c.1141N>A | p.Glu381Lys | p.E381K | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SUSD4 | insertion | Frame_Shift_Ins | novel | c.254_255insTAAAGTGCTTACTTCTCCACGGAAGC | p.Gln86LysfsTer15 | p.Q86Kfs*15 | Q5VX71 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
SUSD4 | SNV | Missense_Mutation | rs867759201 | c.800N>A | p.Gly267Glu | p.G267E | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
SUSD4 | SNV | Missense_Mutation | rs867759201 | c.800N>A | p.Gly267Glu | p.G267E | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SUSD4 | SNV | Missense_Mutation | | c.1227N>C | p.Gln409His | p.Q409H | Q5VX71 | protein_coding | deleterious(0.01) | possibly_damaging(0.641) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |